{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
Paleno 24 Survey
  1. How many Breast cancer patients do you see every month in your clinical practice? *
    2. a
    b
    c
    d
  2. In your clinical practice, what is percentage-wise split of breast cancer patients in following status? *
    3. Hormone receptor positive
    %
    HER2 positive
    %
    Triple negative breast cancer
    %
  3. In your clinical practice, what percentage of HR+ve breast cancer patients would be having metastatic disease? *
    4. a %
    b %
  4. In your clinical practice, What percentage of HR+ve early breast cancer patients have high-risk disease? *
    5. %
  5. Do you routinely do Ki-67 test in newly diagnosed patients with high risk early breast cancer? (Please tick) *

  6. Do you prefer to use CDK4/6 inhibitor in high risk HR+ve early breast cancer? *

  7. In unaffordable patients, would you consider to use palbociclib in high risk HR+ve early breast cancer or you would like to reserve it for advanced or metastatic stage? *

  8. If affordability is not a concern, which CDK4/6 inhibitors do prefer to prescribe in HR+ ve metastatic breast cancer and why? *

  9. Do you feel all the CDK4/6 inhibitors are equally efficacious in HR+ve mBC? *

  10. In your clinical practice, what percentage of HR+ve mBC patients have endocrine resistant disease? *
    11. %
  11. In your clinical practice, what percentage of postmenopausal HR+ mBC patients are on, *
    12. Letrozole
    %
    Anastrozole
    %
    %
  12. In your clinical practice, which ovarian suppression method do you prefer in pre-menopausal HR+ve mBC patients? *

  13. In your clinical practice, what percentage of HR+ve BC patients on palbociclib suffer from Grade >3 neutropenia? *
    14. %
  14. What percentage of HR+ve BC patients on palbociclib requires either dose reduction or treatment discontinuation? *
    15. Dose Reduction
    %
    Treatment discontinuation
    %
  15. In which set of HR+ve breast cancer patients would you start palbociclib at lower dose (75mg or 100mg)? *
    16. a
    b
    c
    d